Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalabrutinib + vistusertib
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acalabrutinib + vistusertib is an experimental combination therapy consisting of two small molecule inhibitors: **acalabrutinib**, a selective covalent inhibitor of Bruton tyrosine kinase (BTK), and **vistusertib**, a selective dual inhibitor of mammalian target of rapamycin complexes 1 and 2 (mTORC1/2). This drug combination was investigated primarily in relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Acalabrutinib blocks B-cell receptor signaling through BTK inhibition, while vistusertib targets the mTOR pathway, which is critical for cell growth and survival.
- Brand names
- none
- Other names
- acalabrutinib + AZD2014Calquence + AZD2014
02
Targets
BMX (Bone Marrow Tyrosine Kinase X-linked)Mechanistic target of rapamycin kinase complex 2ERBB4 (Erb-b2 receptor tyrosine kinase 4)Mechanistic target of rapamycin complex 1BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on acalabrutinib + vistusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalabrutinib + vistusertib.